OrsoBio

Human liver
#Liver disease #OrsoBio #Phase II trial

LXR inverse agonist shows promise in liver disease

A liver-targeted LXR inverse agonist has been found to produce rapid, substantial reductions in triglycerides in patients with severe hypertriglyceridemia (SHTG) and metabolic dysfunction-associated steatoticliver disease (MASLD).  OrsoBio presented the results from its Phase IIa proof-of-concept study of TLC-2716 at the Endocrine Society’s Annual Meeting (ENDO 2026). Read More

#News